TR1 Research Pivot (2013)

Press release via PR Newswire (archival). This internal page summarizes the announcement for historical context.

In 2013, Alvi Armani announced discontinuation of hair‑cloning research in favor of a natural botanical lane—TR1—citing feasibility and cosmetic‑control concerns with cell replication. The pivot concentrated efforts on a plant‑based approach to follicular miniaturization—historically relevant as a step toward today’s TR6.

View the original release → Read original

Explore the Science Shop Sempre

Key Takeaways

1) Research focus realigned. Hair‑cloning replication faced technical, safety, and cosmetic‑control barriers; resources moved to botanical therapeutics.

2) TR1 outcomes. The release cites up to 38% hair growth in study settings versus conventional comparators (as reported in the PR text).

3) Historical through‑line. The TR1 program can be viewed as a precursor lane that eventually evolved into TR6’s patented multi‑botanical complex.

TR1 Study Images

TR1 Results Chart TR1 Study Summary TR1 2013 Graphic

From TR1 → TR6 (Context)

  • 2013: TR1 focus announced; hair cloning discontinued.
  • 2015–2023: Iterative research across extracts, isolates, and dosing designs.
  • 2024–2025: TR6 patented; introduced intra‑operatively at AlviArmani and topically via Origenere Sempre Foam.

Learn More

Back to Press
Wellness Master Club EIN Presswire noissue PR Newswire